GeoVax Labs, Inc.
GOVXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the. At a $2.1M market cap, GeoVax Labs, Inc. ranks as a micro-cap company within healthcare. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Market Cap
$2.1M
Beta
3.69
P/E (TTM)
—
P/E (Fwd)
-0.24
EPS (TTM)
$-8.84
EPS (Fwd)
$-0.86
ROE
-891.6%
ROA
-256.8%
Cash
$3.1M
Total Debt
$323,141
Free CF
-$10.8M
52W Change
-98.6%
Annual Financials
Cash vs Debt
Where GOVX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GOVX finished 78.30% below its 150-day moving average ($1.06) and 84.03% below its 200-day moving average ($1.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GOVX overbought or oversold?
At the October 20, 2026 close, GOVX's RSI(14) was 11.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.1M in cash comfortably exceeding the $323K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$10.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -891.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $82K to $2.5M.
With a beta above 1.5, GOVX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GOVX.